2026-06-06T05:01:49Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/374012026-02-03T11:30:56Zcom_10630_2254col_10630_37953

00925njm 22002777a 4500 dc Mates-Sánchez, José Manuel author Campos-Sandoval, José Ángel author Márquez-Gómez, Javier author 2018-07 Altered cellular metabolism is a hallmark of cancer. Cancer cells express isoforms of metabolic enzymes that may constitute therapeutic targets. Glutaminase controls glutamine metabolism and their expression correlate with malignancy of tumours. The two types of glutaminase isoenzymes, GLS and GLS2, differ in their expression patterns and functional roles: GLS has oncogenic properties and GLS2 has been described as a tumour suppressor factor. Selective genomic and epigenomic intervention over glutaminase affects the metabolic reprogramming of cancer. This review highlights the molecular metabolic vulnerabilities in various types of cancer, to be used for biomarker development, drug design, and in personalized oncology. José M. Matés, José A. Campos-Sandoval, Javier Márquez, Glutaminase isoenzymes in the metabolic therapy of cancer, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Volume 1870, Issue 2, 2018, Pages 158-164, ISSN 0304-419X, https://doi.org/10.1016/j.bbcan.2018.07.007. (https://www.sciencedirect.com/science/article/pii/S0304419X1830101X) https://hdl.handle.net/10630/37401 10.1016/j.bbcan.2018.07.007 Cáncer - Aspectos moleculares Antiangiogénicos Glutaminase isoenzymes in the metabolic 1 therapy of cancer